Health Care · Pharmaceutical Preparations

JANX Janux Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 181771369 filings
Russell 2000

JANX at a glance

Janux Therapeutics, Inc. (JANX, SEC CIK 1817713) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as July 31, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Janux Therapeutics, Inc. (JANX) reported revenue of $10.0 million (down 5.6% from FY2024) and a net loss of $113.6 million. Diluted EPS was -$1.83.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Janux Therapeutics, Inc. (JANX) shares worth $372.1 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$10.0M
−5.6% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$372.1M · +0 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Collaboration revenue $9.3M, down $0.7M YoY, BMS revenue offsetting lower Merck revenue
  • Net loss $21.6M vs $24.3M YoY, operating loss $31.3M vs $35.3M
  • JANX007 highest R&D spend at $6.7M, up $0.5M; JANX013 lowest at $1.0M, down $2.6M
  • Cash, restricted cash and short-term investments $946.5M; operating cash use $25.0M vs $53.7M YoY
  • Existing liquidity expected to fund operations and capital expenditures through at least the next 12 months; clinical spending headwind

Risk Factors

  • Clinical discontinuation of JANX008 in April 2026 after Phase 1a activity proved insufficient versus other pipeline programs
  • Regulatory risk: U.S. FDA staffing cuts may delay IND reviews, guidance and future approvals
  • Manufacturing concentration: BDS for each product candidate expected to rely on single-source suppliers
  • Liquidity risk: $945.7 million in cash, equivalents and short-term investments funds operations for at least 12 months
  • Competitive risk: larger biopharmaceutical companies may develop safer, more effective or cheaper immunotherapies faster

AI summary of the JANX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Investor-relevant figures and management commentary contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 net loss $21.6M, or $0.34 per share, improved from $24.3M, or $0.39, year over year
  • Cash, equivalents and short-term investments $945.7M, down from $966.6M at December 31, 2025, supporting multiple clinical programs
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 collaboration revenue $10.3M; net loss narrowed to $22.0M from $33.9M year over year
  • Cash, equivalents and short-term investments $970.9M, supporting multiple clinical programs

Item 2.02: Results of Operations and Financial Condition

  • Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
  • Press release attached as Exhibit 99.1, containing the substantive financial details
Filed Jun 23, 2026Full analysis →

Item 8.01: Other Events

  • Chief Medical Officer William Go, M.D., Ph.D. departed June 23, 2026, in a termination without “Cause”
  • Successor search underway, with existing clinical leadership assuming interim responsibilities

AI summaries of JANX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for JANX

Don't miss the next JANX filing

  • Alerts as it files. A push when JANX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut JANX, by share count.
  • Ask anything. An AI agent that reads every JANX filing and answers with sources.

JANX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Campbell David AlanGJul 31, 2026-
Campbell David AlanMJul 8, 2026-
Campbell David AlanMJul 8, 2026$4.21
Kung WinstonAJun 11, 2026-
CAPPS VICKIE LAJun 11, 2026-
CAPPS VICKIE LAJun 11, 2026-
Simson JakeAJun 11, 2026-
Barrett Ronald WAJun 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$10.6M$10.0M
Operating Income--$98.8M-$157.7M
Net Income-$58.3M-$69.0M-$113.6M
Op. Margin--933.6%-1576.7%
Net Margin--651.6%-1136.3%
Balance Sheet
Total Assets$380.4M$1.1B$1.0B
Equity-$1.0B$956.8M
ROE--6.7%-11.9%
Per Share
EPS$-1.32$-1.28$-1.83
Cash Flow
Operating CF--$43.8M-$82.2M
CapEx$1.9M$359K$1.0M

Source: XBRL data in Janux Therapeutics, Inc. (JANX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate JANX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
JANX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$372.1M
Q2 202625$353.5M
Q1 202624$245.0M
Q4 202520$283.1M
Q3 202522$571.3M
Q2 202523$532.7M
Q1 202519$458.3M
Q4 202416$797.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

JANX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 31, 2026--
4Jul 10, 2026--
8-KJun 23, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
8-KJun 12, 2026Analysis-
4Jun 12, 2026--
4Jun 4, 2026-
4May 13, 2026-
SC 13GMay 12, 2026-
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
SC 13GApr 29, 2026-
SC 13GApr 29, 2026-
8-KApr 28, 2026Analysis-
8-KFeb 26, 2026Analysis-
10-KFeb 26, 2026-

Related Health Care companies

All Health Care →

JANX SEC filings: frequently asked questions

Which institutions hold JANX stock?

As of September 30, 2026, the largest Janux Therapeutics, Inc. (JANX) holders among the 13F filers tracked by SignalX were BlackRock ($112.9 million), State Street Corp ($39.9 million), Vanguard Capital Management LLC ($37.2 million), Two Sigma Investments ($31.9 million), D.E. Shaw & Co ($26.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was JANX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Janux Therapeutics, Inc. (JANX) reported revenue of $10.0 million (down 5.6% from FY2024) and a net loss of $113.6 million. Diluted EPS was -$1.83. The figures come from the XBRL data in the 10-K.

What did JANX report in its latest 8-K?

Janux Therapeutics, Inc. (JANX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.

What are the latest JANX SEC filings?

Janux Therapeutics, Inc. (JANX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on July 31, 2026.

What is JANX's SEC CIK number?

Janux Therapeutics, Inc. (JANX)'s SEC Central Index Key (CIK) is 1817713. EDGAR lists every JANX filing under that number.

Ask anything about JANX

The research agent reads JANX's filings, financials, insider trades and 13F holders, then answers with sources.